Development of predictive 3D-QSAR CoMFA and CoMSIA models for β-aminohydroxamic acid-derived tumor necrosis factor-α converting enzyme inhibitors

Chemical Biology and Drug Design

Volumn 73, Issue 1, 2009, Pages 97-107

  Murumkar, Prashant R ^a   Gupta, Shirshendu Das ^a   Zambre, Vishal P ^a   Giridhar, Rajani ^a   Yadav, Mange Ram ^a  

^a M S UNIVERSITY OF BARODA   (India)

Author keywords

3D QSAR; CoMFA; CoMSIA; IK 682; TACE inhibitors; TNF converting enzyme

Indexed keywords

HYDROXAMIC ACID DERIVATIVE; IK 682; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; COMPARATIVE MOLECULAR FIELD ANALYSIS; COMPARATIVE MOLECULAR SIMILARITY INDICES ANALYSIS; DRUG DESIGN; DRUG MECHANISM; MOLECULAR MODEL; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

ADAM PROTEINS; COMPUTER SIMULATION; DRUG DESIGN; ENZYME INHIBITORS; HYDROXAMIC ACIDS; LACTAMS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; REPRODUCIBILITY OF RESULTS;

EID: 58149102483     PISSN: 17470277     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2008.00737.x     Document Type: Article

References (38)

1. Aggarwal B.B., Kohr W.J., Hass P.E., Moffat B., Spencer S.A., Henzel W.J., Bringman T.S., Nedwin G.E., Goeddel D.V., Harkins R.N. (1985) Human tumor necrosis factor. Production, purification, and characterization. J Biol Chem 260 : 2345 2354.
2. Bemelmans M.H., vanTits L.J., Buurman W.A. (1996) Tumor necrosis factor: function, release and clearance. Crit Rev Immunol 16 : 1 11.
3. Braun J., Van der Heijde D. (2003) Novel approaches in the treatment of ankylosing spondylitis and other spondyloarthritides. Expert Opin Investig Drugs 12 : 1097 1109.
4. Mikuls T., Moreland L. (2001) TNF blockade in the treatment of rheumatoid arthritis: infliximab versus etanercept. Exp Opin Pharmacother 2 : 75 84.
5. Black R.A., Rouch C.T., Kozlosky C.R., Peschon J.J., Slack J.L., Wolfson M.F., Castner B.J. et al. (1997) A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells. Nature 385 : 729 732.
6. Moss M.L., White J.M., Lambert M.H., Andrews R.C. (2001) TACE and other ADAM proteases as targets for drug discovery. Drug Discov Today 6 : 417 426.
7. Skotnicki J.S., DiGrandi M.J., Levin J.I. (2003) Design strategies for the identification of MMP-13 and TACE inhibitors. J Curr Opin Drug Discov Devel 6 : 742 759.
8. Wasserman Z.R., Duan J.J., Voss M.E., Xue C.B., Cherney R.J., Nelson D.J., Hardman K.D., Decicco C.P. (2003) Identification of a selectivity determinant for inhibition of tumor necrosis factor-alpha converting enzyme by comparative modeling. Chem Biol 10 : 215 223.
9. Xue C.B., He X., Corbett R.L., Roderick J., Wasserman Z.R., Liu R.Q., Jaffee B.D., Covington M.B., Qian M., Trzaskos J.M., Newton R.C., Magolda R.L., Wexler R.R., Decicco C.P. (2001) Discovery of macrocyclic hydroxamic acids containing biphenylmethyl derivatives at P1′, a series of selective TNF-alpha converting enzyme inhibitors with potent cellular activity in the inhibition of TNF-alpha release J. Med Chem 44 : 3351 3354.
10. Rabinowitz M.H., Andrews R.C., Becherer J.D., Bickett D.M., Bubacz D.G., Conway J.G., Cowan D.J., Gual M., Glennon K., Lambert M.H., Leesnitzer M.A., McDougald D.L., Moss M.L., Musso D.L., Rizzolio M.C. (2001) Design of selective and soluble inhibitors of tumor necrosis factor-alpha converting enzyme (TACE). J Med Chem 44 : 4252 4267.
11. Holms J., Mast K., Marcotte P., Elmore I., Li J., Pease L., Glaser K., Morgan D., Michaelides M., Davidsen S. (2001) Discovery of selective hydroxamic acid inhibitors of tumor necrosis factor-alpha converting enzyme. Bioorg Med Chem Lett 11 : 2907 2910.
12. Chen J.M., Jin G., Sung A., Levin J.I. (2002) Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 1: Structure-based design of novel acetylenic P1′ groups. Bioorg Med Chem Lett 12 : 1195 1198.
13. Cherney R.J., Duan J.J., Voss M.E., Chen L., Wang L., Meyer D.T., Wasserman Z.R. et al. (2003) Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-alpha converting enzyme inhibitors. J Med Chem 46 : 1811 1823.
14. Duan J.J., Ott G.R., King B.W., Maduskuie T.P., Xue C.B., Chen L., Lu Z. et al. (2003) Design, Synthesis and Evaluation of β-Amino Hydroxamic Acids as Selective Tumor Necrosis Factor-α Converting Enzyme Inhibitors. Washington, D.C. : American Chemical Society. Abstracts of papers, 226th ACS National Meeting, New York, NY, USA, September 7-11, MEDI-201.
15. Ott G.R., Lu Z., Asakawa N., Covington M.B., Qian M.Q., Liu R.Q., Newton R.C., Christ D.D., Decicco C.P., Duan J.J. (2004) Design, Synthesis and Evaluation of β-Benzamido Hydoxamic Acid Inhibitors of TNF-α Converting Enzyme (TACE). Washington, D.C. : American Chemical Society. Abstracts of Papers, 228th ACS National Meeting, Philadelphia, PA, USA, August 22-26 MEDI-324.
16. Gilmore J.L., King B.W., Harris C., Maduskuie T., Mercer S.E., Liu R.Q., Covington M.B., Qian M., Ribadeneria M.D., Vaddi K., Trzaskos J.M., Newton R.C., Decicco C.P., Duan J.J. (2006) Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors. Bioorg Med Chem Lett 16 : 2699 2704.
17. Cramer R.D. III., Patterson D.E., Bunce J.D. (1988) Comparative molecular field analysis (CoMFA) 1. Effect of shape on binding steroids to carrier proteins. J Am Chem Soc 110 : 5959 5967.
18. Talale T.T., Kulkarni S.S., Kulkarni V.M. (1999) Development of pharmacophore alignment models as input for comparative molecular field analysis of a diverse set of azole antifungal agents. J Chem Inf Comput Sci 39 : 958 966.
19. Murthy V.S., Kulkarni V.M. (2002) 3D-QSAR CoMFA and CoMSIA on protein tyrosine phosphatase 1B inhibitors. Bioorg Med Chem 10 : 2267 2282.
20. Gohlke H., Klebe G. (2002) DrugScore meets CoMFA: adaptation of fields for molecular comparison (AFMoC) or how to tailor knowledge-based pair-potentials to a particular protein. J Med Chem 45 : 4153 4170.
21. Cramer R.D. (2003) Topomer CoMFA: a design methodology for rapid lead optimization. J Med Chem 46 : 374 388.
22. Klebe G., Abraham U., Mietzner T. (1994) Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J Med Chem 37 : 4130 4146.
23. Bohm M., Sturzebecher J., Klebe G. (1999) Three-dimensional quantitative structure-activity relationship analyses using comparative molecular field analysis and comparative molecular similarity indices analysis to elucidate selectivity differences of inhibitors binding to trypsin, thrombin, and factor Xa. J Med Chem 42 : 458 477.
24. Klebe G. (1998) Comparative molecular similarity indices analysis: CoMSIA. Perspect Drug Discov Des 12 : 87 104.
25. Murumkar P.R., Giridhar R., Yadav M.R. (2008) 3D-quantitative structure-activity relationship studies on benzothiadiazepine hydroxamates as inhibitors of tumor necrosis factor-alpha converting enzyme. Chem Biol Drug Des 71 : 363 373.
26. Puntambekar D.S., Giridhar R., Yadav M.R. (2008) Insights into the structural requirements of farnesyltransferase inhibitors as potential anti-tumor agents based on 3D-QSAR CoMFA and CoMSIA models. Eur J Med Chem 43 : 142 154.
27. Puntambekar D.S., Giridhar R., Yadav M.R. (2006) 3D-QSAR studies of farnesyltransferase inhibitors: a comparative molecular field analysis approach. Bioorg Med Chem Lett 16 : 1821 1827.
28. Puntambekar D.S., Giridhar R., Yadav M.R. (2006) Understanding the antitumor activity of novel tricyclicpiperazinyl derivatives as farnesyltransferase inhibitors using CoMFA and CoMSIA. Eur J Med Chem 41 : 1279 1292.
29. Puntambekar D.S., Giridhar R., Yadav M.R. (2006) 3D-QSAR CoMFA/CoMSIA studies on 5-aryl-2,2-dialkyl-4-phenyl-3(2H)-furanone derivatives, as selective COX-2 inhibitors. Acta Pharm 56 : 157 174.
30. Chen X.T., Ghavimi B., Corbett R.L., Xue C.B., Liu R.Q., Covington M.B., Qian M., Vaddi K., Christ D.D., Hardman K.D., Ribadeneria M.D., Trzaskos J.M., Newton R.C., Decocco C.P., Duan J.J. (2007) A new 4-(2-methylquinolin-4- ylmethyl)phenyl P1′ group for the beta-amino hydroxamic acid derived TACE inhibitors. Bioorg Med Chem Lett 17 : 1865 1870.
31. Stewart J.J. (1990) MOPAC: a semiempirical molecular orbital program. J Comput Aided Mol Des 4 : 1 105.
32. Dewar M.J., Zoebisch E.G., Healy E.F., Stewart J.P. (1985) Development and use of quantum mechanical molecular models. 76. AM1: a new general purpose quantum mechanical molecular model. J Am Chem Soc 107 : 3902 3909.
33. Friesner R.A., Banks J.L., Murphy R.B., Halgren T.A., Klicic J.J., Mainz D.T., Repasky M.P., Knoll E.H., Shelley M., Perry J.K., Shaw D.E., Francis P., Shenkin P.S. (2004) Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 47 : 1739 1749.
34. Halgren T.A. (1990) Maximally diagonal force constants in dependent angle-bending coordinates. II. Implications for the design of empirical force fields. J Am Chem Soc 112 : 4710 4723.
35. Podlogar B.L., Fergusson D.M. (2000) QSAR and CoMFA: a perspective on the practical application to drug discovery. Drug Des Discov 17 : 4 12.
36. Clark M., Cramer R.D. III., Jones D., Patterson D.E., Simeroth P. (1990) Comparative molecular field analysis (CoMFA). 2. Toward its use with 3D-structural databases. Tetrahedron Comput Methodol 3 : 47 59.
37. Cho S.J., Tropsha A. (1995) Cross-validated R2-guided region selection for comparative molecular field analysis: a simple method to achieve consistent results. J Med Chem 38 : 1060 1066.
38. Duan J.J., Chen L., Wasserman Z.R., Lu Z., Liu R.Q., Covington M.B., Qian M., Hardman K.D., Magolda R.L., Newton R.C., Christ D.D., Wexler R.R., Decicco C.P. (2002) Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structure-activity relationships. J Med Chem 45 : 4954 4957.